Treatment Options - RFA Therapy
Radiofrequency ablation (RFA) has been studied in many clinical trials since
2003 in the United States and Europe. Results have been published in over
40 articles in peer-reviewed medical journals such as The New England
Journal of Medicine. Outcomes have shown that RFA is safe and effective
for treating all types of Barrett’s tissue. Most demonstrate that Barrett’s
tissue can be completely eliminated with RFA in greater than 98% of patients
who receive treatment.
Over 1,000 physicians have performed over 60,000 RFA procedures. In the
largest patient cohort available to date, the U.S. HALO Patient Registry,
approximately 50% of patients have non-dysplastic Barrett's esophagus,
indicating a trend toward earlier intervention among physicians utilizing this
Click to view information about clinical trials.
Examples of key clinical findings include20, 21, 22, 28, 29,
- Complete clearance of non-dysplastic Barrett's esophagus in 98.4% of
patients at two and a half year follow-up. 7
- Outstanding safety profile with a less than or equal to 6% stricture
rate**, less than 0.02% perforation rate, and no associated
deaths.14 (Based on safety data through June 2010.)
- Overall, complete eradication of non-dysplastic and dysplastic
Barrett's esophagus at rates exceeding 90% has been shown in numerous
- Elimination of abnormal genetic markers associated with Barrett's
esophagus after RFA therapy.
- No change in the function of the esophagus after RFA therapy.
* Important Reminder: This information is not intended as a definitive
basis for diagnosis or treatment in any particular case. It is very important
that you consult your doctor about your specific condition, contraindications,
and possible complications.
** Data is based on RFA performed according to manufacturer's